Subgroup analysis by Ki-67 and baseline CgA of the randomized, placebo-controlled phase 3 study of surufatinib in advanced well-differentiated pancreatic neuroendocrine tumors (SANET-p).
In: Journal of clinical oncology, Jg. 39 (2021), Heft 15 suppl, S. 4111-4111
Online
serialPeriodical
Zugriff:
Titel: |
Subgroup analysis by Ki-67 and baseline CgA of the randomized, placebo-controlled phase 3 study of surufatinib in advanced well-differentiated pancreatic neuroendocrine tumors (SANET-p).
|
---|---|
Autor/in / Beteiligte Person: | Yu, Xianjun ; Xu, Jianming ; Shen, Lin ; Bai, Chunmei ; Li, Jie ; Zhou, Zhiwei ; Li, Zhiping ; LI, Enxiao ; Yuan, Xianglin ; Chi, Yihebali ; Yin, Yongmei ; Lou, Wenhui ; Xu, Nong ; Bai, Yuxian ; Zhang, Tao ; Xiu, Dianrong ; Wang, Xiuwen ; Guan, Sha ; Xu, Qian ; Su, Weiguo |
Link: | |
Zeitschrift: | Journal of clinical oncology, Jg. 39 (2021), Heft 15 suppl, S. 4111-4111 |
Veröffentlichung: | 2021 |
Medientyp: | serialPeriodical |
ISSN: | 0732-183X (print) |
Sonstiges: |
|